Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)

Inclusion 1. Histologically confirmed, unresectable advanced or metastatic biliary tract, including cholangiocarcinoma (intrahepatic or extrahepatic) and gallbladder carcinoma. 2. Patients with previously untreated disease if unresectable or metastatic at initial diagnosis will be eligible. 3. Patient with recurrent disease >6 months after curative surgery or >6 months after the completion of adjuvant therapy (chemotherapy and/or radiation) will be eligible. 4. WHO/ECOG PS of 0 or 1 Exclusion 1. History of another primary malignancy 2. Brain metastases or spinal cord compression 3. Uncontrolled intercurrent illness 4. Major surgical procedure within 28 days prior to the first dose of IP. 5. Prior locoregional therapy such as radioembolization

Additional locations may be listed on ClinicalTrials.gov for NCT03875235.

See trial information on ClinicalTrials.gov for a list of participating sites.

A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International

Study of Durvalumab in Combination with Gemcitabine Plus Cisplatin Versus Placebo in

Combination with Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary

Tract Cancers.

Trial PhasePhase III

Trial Typetreatment

Lead OrganizationAstraZeneca Pharmaceuticals LP

Description